234 related articles for article (PubMed ID: 12891224)
1. Pharmacokinetic drug interactions in children taking oxcarbazepine.
Sallas WM; Milosavljev S; D'souza J; Hossain M
Clin Pharmacol Ther; 2003 Aug; 74(2):138-49. PubMed ID: 12891224
[TBL] [Abstract][Full Text] [Related]
2. Drug interaction and pharmacokinetic modeling of oxcarbazepine in korean patients with epilepsy.
Park KJ; Kim JR; Joo EY; Seo DW; Hong SB; Ko JW; Kim SR; Huh W; Lee SY
Clin Neuropharmacol; 2012; 35(1):40-4. PubMed ID: 22246398
[TBL] [Abstract][Full Text] [Related]
3. Lack of pharmacokinetic interaction between oxcarbazepine and lamotrigine.
Theis JG; Sidhu J; Palmer J; Job S; Bullman J; Ascher J
Neuropsychopharmacology; 2005 Dec; 30(12):2269-74. PubMed ID: 16052246
[TBL] [Abstract][Full Text] [Related]
4. Oxcarbazepine in infants and young children with partial seizures.
Northam RS; Hernandez AW; Litzinger MJ; Minecan DN; Glauser TA; Mangat S; Zheng C; Souppart C; Sturm Y
Pediatr Neurol; 2005 Nov; 33(5):337-44. PubMed ID: 16243221
[TBL] [Abstract][Full Text] [Related]
5. Population pharmacokinetics of oxcarbazepine and its monohydroxy derivative in epileptic children.
Rodrigues C; Chiron C; Rey E; Dulac O; Comets E; Pons G; Jullien V
Br J Clin Pharmacol; 2017 Dec; 83(12):2695-2708. PubMed ID: 28771787
[TBL] [Abstract][Full Text] [Related]
6. Oxcarbazepine pharmacokinetics and tolerability in children with inadequately controlled epilepsy.
Rey E; Bulteau C; Motte J; Tran A; Sturm Y; D'Souza J; Markabi S; Pons G; Dulac O
J Clin Pharmacol; 2004 Nov; 44(11):1290-300. PubMed ID: 15496647
[TBL] [Abstract][Full Text] [Related]
7. Overview of the clinical pharmacokinetics of oxcarbazepine.
Flesch G
Clin Drug Investig; 2004; 24(4):185-203. PubMed ID: 17516704
[TBL] [Abstract][Full Text] [Related]
8. Relative bioavailability, metabolism and tolerability of rectally administered oxcarbazepine suspension.
Clemens PL; Cloyd JC; Kriel RL; Remmel RP
Clin Drug Investig; 2007; 27(4):243-50. PubMed ID: 17358096
[TBL] [Abstract][Full Text] [Related]
9. Clinical pharmacokinetics of antiepileptic drugs in paediatric patients. Part II. Phenytoin, carbamazepine, sulthiame, lamotrigine, vigabatrin, oxcarbazepine and felbamate.
Battino D; Estienne M; Avanzini G
Clin Pharmacokinet; 1995 Nov; 29(5):341-69. PubMed ID: 8582119
[TBL] [Abstract][Full Text] [Related]
10. Rufinamide: clinical pharmacokinetics and concentration-response relationships in patients with epilepsy.
Perucca E; Cloyd J; Critchley D; Fuseau E
Epilepsia; 2008 Jul; 49(7):1123-41. PubMed ID: 18503564
[TBL] [Abstract][Full Text] [Related]
11. Clinical pharmacokinetics of oxcarbazepine.
May TW; Korn-Merker E; Rambeck B
Clin Pharmacokinet; 2003; 42(12):1023-42. PubMed ID: 12959634
[TBL] [Abstract][Full Text] [Related]
12. Clinical, cognitive, and neurophysiologic correlates of short-term treatment with carbamazepine, oxcarbazepine, and levetiracetam in healthy volunteers.
Mecarelli O; Vicenzini E; Pulitano P; Vanacore N; Romolo FS; Di Piero V; Lenzi GL; Accornero N
Ann Pharmacother; 2004 Nov; 38(11):1816-22. PubMed ID: 15367726
[TBL] [Abstract][Full Text] [Related]
13. Population pharmacokinetic analysis for 10-monohydroxy derivative of oxcarbazepine in pediatric epileptic patients shows no difference between Japanese and other ethnicities.
Sugiyama I; Bouillon T; Yamaguchi M; Suzuki H; Hirota T; Fink M
Drug Metab Pharmacokinet; 2015 Apr; 30(2):160-7. PubMed ID: 25989891
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetic variability of four newer antiepileptic drugs, lamotrigine, levetiracetam, oxcarbazepine, and topiramate: a comparison of the impact of age and comedication.
Johannessen Landmark C; Baftiu A; Tysse I; Valsø B; Larsson PG; Rytter E; Johannessen SI
Ther Drug Monit; 2012 Aug; 34(4):440-5. PubMed ID: 22777154
[TBL] [Abstract][Full Text] [Related]
15. Oxcarbazepine, an antiepileptic agent.
Kalis MM; Huff NA
Clin Ther; 2001 May; 23(5):680-700; discussion 645. PubMed ID: 11394728
[TBL] [Abstract][Full Text] [Related]
16. Usefulness of oral loading of oxcarbazepine suspension in selected patients with epilepsy.
Kim DW; Gu N; Lee H; Jang IJ; Chu K; Yu KS; Cho JY; Yoon SH; Na HJ; Lee SK
Int J Clin Pharmacol Ther; 2013 Oct; 51(10):780-6. PubMed ID: 23849326
[TBL] [Abstract][Full Text] [Related]
17. The effect of renal impairment on the pharmacokinetics of oxcarbazepine and its metabolites.
Rouan MC; Lecaillon JB; Godbillon J; Menard F; Darragon T; Meyer P; Kourilsky O; Hillion D; Aldigier JC; Jungers P
Eur J Clin Pharmacol; 1994; 47(2):161-7. PubMed ID: 7859804
[TBL] [Abstract][Full Text] [Related]
18. Effects of felbamate on the pharmacokinetics of the monohydroxy and dihydroxy metabolites of oxcarbazepine.
Hulsman JA; Rentmeester TW; Banfield CR; Reidenberg P; Colucci RD; Meehan JW; Radwanski E; Mojaverian P; Lin CC; Nezamis J
Clin Pharmacol Ther; 1995 Oct; 58(4):383-9. PubMed ID: 7586929
[TBL] [Abstract][Full Text] [Related]
19. Oxcarbazepine adjunctive therapy in infants and young children with partial seizures.
Piña-Garza JE; Espinoza R; Nordli D; Bennett DA; Spirito S; Stites TE; Tang D; Sturm Y
Neurology; 2005 Nov; 65(9):1370-5. PubMed ID: 16275822
[TBL] [Abstract][Full Text] [Related]
20. Efficacy, tolerability, and pharmacokinetics of oxcarbazepine oral loading in patients with epilepsy.
Kim DW; Gu N; Jang IJ; Chu K; Yu KS; Cho JY; Yoon SH; Kim HS; Oh J; Lee SK
Epilepsia; 2012 Jan; 53(1):e9-12. PubMed ID: 22091603
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
